305 related articles for article (PubMed ID: 32536918)
21. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
[TBL] [Abstract][Full Text] [Related]
22. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
24. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
25. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
[TBL] [Abstract][Full Text] [Related]
26. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
Bontkes HJ; Moreno M; Hangalapura B; Lindenberg JJ; de Groot J; Lougheed S; van der Vliet HJ; van den Eertwegh AJ; de Gruijl TD; von Blomberg BM; Scheper RJ
Clin Immunol; 2010 Sep; 136(3):364-74. PubMed ID: 20570567
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
28. Spatial distribution of IL4 controls iNKT cell-DC crosstalk in tumors.
Wang L; Liu Z; Wang L; Wu Q; Li X; Xie D; Zhang H; Zhang Y; Gu L; Xue Y; Yue T; Liu G; Ji W; Wei H; Xu T; Bai L
Cell Mol Immunol; 2020 May; 17(5):496-506. PubMed ID: 31160756
[TBL] [Abstract][Full Text] [Related]
29. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
30. Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen.
Ruben JM; Bontkes HJ; Westers TM; Hooijberg E; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
Cancer Immunol Immunother; 2015 Nov; 64(11):1419-27. PubMed ID: 26216454
[TBL] [Abstract][Full Text] [Related]
31. Quantitative and qualitative iNKT repertoire associations with disease susceptibility and outcome in macaque tuberculosis infection.
Chancellor A; White A; Tocheva AS; Fenn JR; Dennis M; Tezera L; Singhania A; Elliott T; Tebruegge M; Elkington P; Gadola S; Sharpe S; Mansour S
Tuberculosis (Edinb); 2017 Jul; 105():86-95. PubMed ID: 28610792
[TBL] [Abstract][Full Text] [Related]
32. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells.
Hermans IF; Silk JD; Gileadi U; Masri SH; Shepherd D; Farrand KJ; Salio M; Cerundolo V
J Immunol; 2007 Mar; 178(5):2721-9. PubMed ID: 17312114
[TBL] [Abstract][Full Text] [Related]
34. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
35. Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression.
Neumann S; Young K; Compton B; Anderson R; Painter G; Hook S
Vaccine; 2015 Oct; 33(43):5838-5844. PubMed ID: 26363382
[TBL] [Abstract][Full Text] [Related]
36. Activation of invariant natural killer T cells by α-galactosylceramide ameliorates myocardial ischemia/reperfusion injury in mice.
Homma T; Kinugawa S; Takahashi M; Sobirin MA; Saito A; Fukushima A; Suga T; Takada S; Kadoguchi T; Masaki Y; Furihata T; Taniguchi M; Nakayama T; Ishimori N; Iwabuchi K; Tsutsui H
J Mol Cell Cardiol; 2013 Sep; 62():179-88. PubMed ID: 23774048
[TBL] [Abstract][Full Text] [Related]
37. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
[TBL] [Abstract][Full Text] [Related]
38. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
39. Role of leukotriene B4 12-hydroxydehydrogenase in α-galactosylceramide-pulsed dendritic cell therapy for non-small cell lung cancer.
Tanaka K; Kanesaka Y; Takami M; Suzuki A; Hosokawa H; Onodera A; Kamata T; Nagato K; Nakayama T; Yoshino I; Motohashi S
Biochem Biophys Res Commun; 2018 Nov; 506(1):27-32. PubMed ID: 30336981
[TBL] [Abstract][Full Text] [Related]
40. Glycolipid-Containing Nanoparticle Vaccine Engages Invariant NKT Cells to Enhance Humoral Protection against Systemic Bacterial Infection but Abrogates T-Independent Vaccine Responses.
Shute T; Amiel E; Alam N; Yates JL; Mohrs K; Dudley E; Salas B; Mesa C; Serrata A; Angel D; Vincent BK; Weyers A; Lanthier PA; Vomhof-Dekrey E; Fromme R; Laughlin M; Durham O; Miao J; Shipp D; Linhardt RJ; Nash K; Leadbetter EA
J Immunol; 2021 Apr; 206(8):1806-1816. PubMed ID: 33811104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
